Phase II Study, Multicenter, Open-Label, Evaluating Efficacy of Treatment With Sutent(Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.

Trial Profile

Phase II Study, Multicenter, Open-Label, Evaluating Efficacy of Treatment With Sutent(Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Cancer metastases; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Dec 2009 Additional trial location (France) identified as reported by ClinicalTrials.gov.
    • 30 Apr 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top